Identity
Glaxosmithkline, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €286.4M | |
| 2025 | €211.3M | |
| 2024 | €216.3M | |
| + regional platforms | ||
| 2023 | €83.2M | |
| 2022 | €87.9M | |
| 2021 | €40.4M | |
| 2020 | €14.4M | |
| 2019 | €8.6M | |
| 2018 | €2.6M | |
| 2017 | €3.5M | |
| 2016 | €1.1M | |
In figures
Volume
Between 2016 and 2026 it won 1,026 contracts worth €956M on its own, with 61 buyers. Its 3 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 36.4%; the middle half of its discounts between 22.6% and 43.8% (26 comparable awards).
Competition
Since 2024, 29% of its comparable value was won with a discount and against other bidders. It was the only bidder in 70% of its contracts (2016–2026).
Renewals
89 contracts (€168M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Glaxosmithkline, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Glaxosmithkline, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 36.4% · middle half between 22.6% and 43.8% · 26 awards
2017–2023: median 15.0% (13 awards) · 2024–2026: median 36.4% (26 awards).
2017–2026: median 29.7% · middle half between 14.6% and 38.5% · 39 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
561 contracts · €713M
By buyer · 2024–2026
Departament de Salut
Productos farmacéuticos
40 contracts · €121M
Órgano de Contratación de la Ciudad Autónoma de Ceuta
Productos farmacéuticos
22 contracts · €912k
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
6 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
46% of the comparable value since 2024 (€54.9M of €120M) was won at the tender price and without other bidders. €34.1M (29%) was awarded with a discount and against other bidders.
Comparable: 58 awards with a published budget and bidder count (€120M of €714M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 61.1% of the value was awarded through negotiated without publicity procedure (40.8% of contracts); followed by Open (22.7%) and Other (10.7%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 89 of its contracts come up for tender again, worth €168M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Servicio de Salud de las Illes Balears | €1.25M |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €170k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €75.5k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €6.17k |
| 2026 | Gobierno Vasco-Dirección de Régimen Jurídico, Económico y Servicios Generales | €9.53 |
and 84 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Consejería de Sanidad (Comunidad de Madrid) | 15 | 226 M | 2024–2026 |
| Departament de Salut | 63 | 191 M | 2020–2026 |
| Servicio Andaluz de Salud | 110 | 99 M | 2024–2026 |
| Consejería de Sanidad de la Junta de Castilla y León | 38 | 71 M | 2018–2026 |
| Secretaría General de la Consejería de Sanidad de la Junta de Comunidades de Castilla-La Mancha | 46 | 54 M | 2018–2026 |
and 56 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,005 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 20/10/2026 | BAM Suministro hepatitis B lote 7 Centro Militar de Farmacia de la Defensa | Inspección General de Sanidad de la Defensa | 1 | €16.1k |
| 09/06/2026 | rc_3º cbam_am_296_2024_glaxosmithkline, s.a. | Servicio Andaluz de Salud | 1 | €241k |
| 08/06/2026 | cpca 1º cbam glaxosmithkline, s.a. exp. 578/2025 suministro medicamentos exclusivos, cca: +6.i+e9q8… | Servicio Andaluz de Salud | 1 | €383k |
| 29/04/2026 | rc_2º cbam_am_296_2024_glaxosmithkline, s.a. | Servicio Andaluz de Salud | 1 | €301k |
| 27/04/2026 | LOTE 4 Vacuna frente a difteria, tétanos, tosferina acelular de contenido antígeno reducido | Consejería de Sanidad del Gobierno de Canarias | 2 | €168k |